Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae355 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Florence Lévesque und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Centre Hospitalier universitaire de Québec, Université Laval, Quebec City, QC, G1J 5B3, Canada. Hauptthemen laut MEDLINE: Molecular Diagnostic Techniques, Thyroid Neoplasms, Thyroid Nodule. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Régie de l'assurance-maladie du Québec, RAMQ, Régie de l’assurance-maladie du Québec.
Abstract (Originalsprache)
Context
Indeterminate thyroid nodules (ITNs) lead to diagnostic surgeries in many countries. The use of molecular testing (MT) is endorsed by several guidelines, but costs are limitative, especially in public health care systems like in Canada.
Objectives
The primary objective of this work was to evaluate the clinical value of ThyroSeq v3 (TSv3) using benign call rate (BCR) in a real-world practice. The secondary objective was to assess the cost-effectiveness of MT.
Methods
This multicentric prospective study was conducted in 5 academic centers in Quebec, Canada. A total of 500 consecutive patients with Bethesda III (on 2 consecutive cytopathologies) or IV and TIRADS 3 or 4 nodules measuring 1 to 4 cm were included. MT was performed between November 2021 and November 2022. Patients with a positive TSv3 were referred for surgery. Patients with a negative TSv3 were planned for follow-up by ultrasonography for a minimum of 2 years. The BCR, corresponding to the proportion of ITNs with negative TSv3 results, was assessed.
Results
A total of 500 patients underwent TSv3 testing, with a BCR of 72.6% (95% CI, 68.5%-76.5%; P < .001). Ultimately, 99.7% of patients with a negative result avoided surgery. The positive predictive value of TSv3 was 68.2% (95% CI, 58.5%-76.9%). The cost-benefit analysis identified that the implementation of MT would yield a cost savings of $6.1 million over the next 10 years.
Conclusion
The use of MT (TSv3) in a well-selected population with ITNs led to a BCR of 72.6%. It is cost-effective and prevents unnecessary surgeries in a public health care setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine, Centre Hospitalier universitaire de Québec, Université Laval, Quebec City, QC, G1J 5B3, Canada.
- Department of Otolaryngology, Head and Neck Surgery, Jewish General Hospital and McGill University Health Centre, Montreal, H3T 1E2, Canada.
- Department of Otolaryngology, Head and Neck Surgery, Centre Hospitalier universitaire de Québec, Université Laval, Quebec City, QC, G1J 1Z4, Canada.
- Division of Endocrinology, Department of Medicine, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal, H2X 0C1, Canada.
- Department of Otolaryngology, Head and Neck Surgery, Centre Hospitalier universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, J1H 5H3, Canada.
- Division of Endocrinology, Department of Medicine, Centre Hospitalier universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, J1H 5H3, Canada.
ORCID-Profile: Richard J Payne, Andrée Boucher, Marie-Hélène Massicotte, Maryse Brassard
Förderung
- Régie de l'assurance-maladie du Québec
- RAMQ
- Régie de l’assurance-maladie du Québec
Zitieren
APA
Lévesque, F., Payne, R. J., Beaudoin, D., Boucher, A., Fortier, P. H., Massicotte, M. H., Pusztaszeri, M., Rondeau, G., Corriveau, E., El Malt, F., & Brassard, M. (2025). Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae355
Vancouver
Lévesque F, Payne RJ, Beaudoin D, Boucher A, Fortier PH, Massicotte MH, et al. Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae355
BibTeX
@article{Lvesque2025,
author = {Lévesque, Florence and Payne, Richard J and Beaudoin, Danielle and Boucher, Andrée and Fortier, Pierre-Hugues and Massicotte, Marie-Hélène and Pusztaszeri, Marc and Rondeau, Geneviève and Corriveau, Edith and El Malt, Farida and Brassard, Maryse},
title = {Publicly Funded Molecular Testing of Indeterminate Thyroid Nodules: Canada's Experience},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae355}
}
EUVIMED